Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Explores AI Content Marketplace With Media Publishers 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
NEW YORK, Nov. 14, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Genocea Biosciences, Inc. ("Genocea Biosciences") (NASDAQ:GNCA) between May 5, 2017 and September 25, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the U.S. District Court for the District of Massachusetts. To get more information go to:
http://www.zlk.com/plsra-c/genocea-biosciences-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's finances were insufficient to support Phase 3 trials of GEN-003; (ii) accordingly, Genocea had overstated the prospects for GEN-003; and (iii) as a result of the foregoing, Genocea's public statements were materially false and misleading at all relevant times.
On September 25, 2017, Genocea disclosed that it was halting spending and activities on GEN-003 and exploring strategic alternatives for the drug. The Company also announced that it was cutting 40% of its workforce.
If you suffered a loss in Genocea Biosciences you have until January 2, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
